| P279 | CRISPR/Cas9 enables the efficient production of allogeneic CAR-T cells engineered to contain multiple genome edits to enhance therapeutic T-cell function | Ashley Porras, BA; Dan Henderson; Sushant Karnik; Katie Levitsky, BS; Demetrios Kalaitzidis, Ph.D.; Jason Sagert, PhD; Zinkal Padalia, MS; Mary Lee Dequeant, PhD; melanie allen, BS; Hanspeter Waldner; Henia Dar, PhD; Chandirasegaran Massilamany, PhD; Paul Tetteh; Dakai Mu, BA; Elaine Huang, PhD; Thao Nguyen; Sarah Spencer, PhD; Kelly Maeng; Jonathan Terrett, PhD | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Solid tumors |
